At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01541 IMMUNEONCO-B
Market Closed 09-27 16:08:28
6.080
+1.080
+21.60%
High6.180
Low5.090
Vol27.98M
Open5.090
D1 Closing5.000
Amplitude21.80%
Mkt Cap2.27B
Tradable Cap2.12B
Total Shares374.16M
T/O163.92M
T/O Rate8.02%
Tradable Shares349.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BRIEF-Instil Bio And Immuneonco Announce Global Registrational Strategy For Pd-L1xvegf Bispecific Antibody, Syn-2510/Imm2510, In Non-Small Cell Lung Cancer And Triple-Negative Breast Cancer
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for Pd-L1xvegf Bispecific Antibody, Syn-2510/Imm2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.'s (HKG:1541) recent 42% pullback adds to one-year year losses, institutional owners may take drastic measures
ImmuneOnco Biopharmaceuticals Shanghai Inc is a China-based company mainly engaged in research and development of testing biotechnology. The Company's main businesses include the development of biotechnology for the systemic utilization of innate and adaptive immunity, and the development of next-generation tumor immunotherapies, which primarily focus on the adaptive immune system. The Company mainly operates its businesses in the domestic and overseas markets.